ELSEVIER

Diabetes Research and Clinical Practice 33 (1996) 199–201

DIABETES RESEARCH AND CLINICAL PRACTICE

Author index

Volume 33 (1996)

Akai, H., see Suzuki, S. **33**, 43
Arnqvist, H.J., see Littorin, B. **33**, 129
Aso, Y., see Inukai, T. **33**, 99

Barone, R., see Signore, A. **33**, 83
Barrientos, A., see Conget, I. **33**, 135
Benedetto, A.D., G. Romano, S. Campo, E. Di Cesare, D. Cucinotta, No evidence of increased fetal haemoglobin in an adult diabetic population **33**, 37
Blohmé, G., see Littorin, B. **33**, 129
Bonfigli, A.R., see Testa, R. **33**, 111
Brown, L.J., see Willis, J.A. **33**, 89

Caixàs, A., see Chico, A. **33**, 105
Campo, S., see Benedetto, A.D. **33**, 37
Cardellach, F., see Conget, I. **33**, 135
Chianelli, M., see Signore, A. **33**, 83
Chico, A., A. Pérez, A. Caixàs, J. Ordóñez, J.M. Pou, A. de Leiva, Lipoprotein(a) concentrations and non-insulin-dependent diabetes mellitus: relationship to glycaemic control and diabetic complications **33**, 105
Conget, I., J.M. Manzanares, A. Barrientos, F. Cardellach, R. Gomis, Coenzyme Q10 and insulin secretion in vitro **33**, 135
Cucinotta, D., see Benedetto, A.D. **33**, 37
Czyżyk, A., see Jasik, M. **33**, 59

de Leiva, A., see Chico, A. **33**, 105
Di Cesare, E., see Benedetto, A.D. **33**, 37
Donnelly, R., see McGill, M.J. **33**, 173

Fiore, V., see Signore, A. **33**, 83
Forbes, L.V., see Willis, J.A. **33**, 89
Fujiwara, Y., see Inukai, T. **33**, 99

Gomis, R., see Conget, I. **33**, 135
Gregorio, F., see Testa, R. **33**, 111

Hepp, K.D., see Mellinghoff, A.C. **33**, 75
Hinokio, Y., see Suzuki, S. **33**, 43
Hirai, A., see Suzuki, S. **33**, 43
Hirai, M., see Suzuki, S. **33**, 43
Hirai, S., see Suzuki, S. **33**, 43
Hirano, T., see Yoshino, G. **33**, 1
Hirashima, T., see Mori, S. **33**, 145

Inoue, S., Y. Lan, J. Muran, M. Tsuji, Reduced hydrogen peroxide production in neutrophils from patients with diabetes **33**, 119
Inukai, T., Y. Fujiwara, K. Tayama, Y. Aso, Y. Takemura, Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin-dependent diabetes mellitus **33**, 99
Ishizawa, M., see Ishizuka, T. **33**, 159
Ishizuka, T., K. Kajita, K. Yamada, A. Miura, Y. Kanoh, M. Ishizawa, H. Wada, S. Itaya, M. Yamamoto, K. Yasuda, K.-i. Nagata, Y. Okano, Insulin regulates PKC isoform mRNA in rat adipocytes **33**, 159
Itakura, M., see Kunika, K. **33**, 181
Itaya, S., see Ishizuka, T. **33**, 159
Iwasaki, N., see Ogata, M. **33**, 71

Jasik, M., A. Kasperska-Dworak, A. Czyżyk, Effect of nifedipine, captopril and prazosin on secretory function of pancreatic β-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics **33**, 59

Kajita, K., see Ishizuka, T. **33**, 159
Kanatsuka, A., see Takada, K. **33**, 153
Kanoh, Y., see Ishizuka, T. **33**, 159
Karibe, S., see Ogata, M. **33**, 71
Kasperska-Dworak, A., see Jasik, M. **33**, 59
Kawano, K., see Mori, S. **33**, 145
Kawasaki, H., see Suzuki, S. **33**, 43
Kazumi, T., see Yoshino, G. **33**, 1
Keinänen-Kiukaanniemi, S., see Qiao, Q. **33**, 191
Kicic, E., T.N. Palmer, Increased white cell aldose reductase mRNA levels in diabetic patients **33**, 31
Kivelä, S.-L., see Qiao, Q. **33**, 191

Kunika, K., T. Yamaoka, M. Itakura, Diabetic damage of selective renal reabsorption assessed by albumin negative charge **33**, 181

Landgraf, R., see Mellinghoff, A.C. **33**, 75
Lan, Y., see Inoue, S. **33**, 119
Lithner, F., see Littorin, B. **33**, 129
Littorin, B., G. Sundkvist, B. Scherstén, L. Nyström, H.J. Arnqvist, G. Blohmé, F. Lithner, L. Wibell, J. Östman, Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS) **33**, 129
Logan, J.L., Studies on the impact of dietary fat composition on proteinuria in diabetic rats **33**, 21
Lunetta, M., M.D. Mauro, Different effect of acute and chronic oral metformin administration on glucose and insulin response to bread and to pasta in non-insulin dependent diabetic patients **33**, 53

MacKay, I.R., see Willis, J.A. **33**, 89
Majchrzak, A.E., see Zozulińska, D.A. **33**, 139
Makino, H., see Takada, K. **33**, 153
Manfrini, S., see Testa, R. **33**, 111
Manzanares, J.M., see Conget, I. **33**, 135
Mauro, M.D., see Lunetta, M. **33**, 53
McGill, M.J., R. Donnelly, L. Molyneaux, D.K. Yue, Ethnic differences in the prevalence of hypertension and proteinuria in NIDDM **33**, 173
Mellinghoff, A.C., A.J. Reininger, L.J. Wurzinger, R. Landgraf, K.D. Hepp, Influence of glycemic control on viscosity and density of plasma and whole blood in Type-1 diabetic patients **33**, 75
Miura, A., see Ishizuka, T. **33**, 159
Molyneaux, L., see McGill, M.J. **33**, 173
Mori, M., see Negishi, M. **33**, 15
Mori, S., K. Kawano, T. Hirashima, T. Natori, Relationships between diet control and the development of spontaneous type II diabetes and diabetic nephropathy in OLETF rats **33**, 145
Muran, J., see Inoue, S. **33**, 119

Nagata, K.-i., see Ishizuka, T. **33**, 159
Natori, T., see Mori, S. **33**, 145
Negishi, M., H. Shimizu, K.-i. Ohtani, M. Mori, Acarbose partially prevents the development of diabetes mellitus by multiple low-dose streptozotocin administration **33**, 15
Negri, M., see Signore, A. **33**, 83
Nishimura, M., see Takada, K. **33**, 153
Nyström, L., see Littorin, B. **33**, 129

Ogata, M., N. Iwasaki, H. Ohgawara, S. Karibe, Y. Omori, Absence of the Gly^{40}–Ser mutation in the glucagon receptor gene in Japanese subjects with NIDDM **33**, 71
Ohgawara, H., see Ogata, M. **33**, 71
Ohtani, K.-i., see Negishi, M. **33**, 15
Ohtomo, M., see Suzuki, S. **33**, 43
Okano, Y., see Ishizuka, T. **33**, 159
Omori, Y., see Ogata, M. **33**, 71
Onoda, M., see Suzuki, S. **33**, 43
Ordóñez, J., see Chico, A. **33**, 105
Östman, J., see Littorin, B. **33**, 129

Palmer, T.N., see Kicic, E. **33**, 31
Paolo Pozzilli, see Signore, A. **33**, 83
Pérez, A., see Chico, A. **33**, 105
Piantanelli, L., see Testa, R. **33**, 111
Pou, J.M., see Chico, A. **33**, 105
Procaccini, E., see Signore, A. **33**, 83

Qiao, Q., S. Keinänen-Kiukaanniemi, U. Rajala, A. Uusimäki, S.-L. Kivelä, Risk for diabetes and persistent impaired glucose tolerance among middle-aged Finns **33**, 191

Rajala, U., see Qiao, Q. **33**, 191
Reininger, A.J., see Mellinghoff, A.C. **33**, 75
Romano, G., see Benedetto, A.D. **33**, 37
Ronga, G., see Signore, A. **33**, 83
Rowley, M.J., see Willis, J.A. **33**, 89

Saito, Y., see Takada, K. **33**, 153
Satoh, Y., see Suzuki, S. **33**, 43
Scherstén, B., see Littorin, B. **33**, 129
Schmidli, R.S., see Willis, J.A. **33**, 89
Scott, R.S., see Willis, J.A. **33**, 89
Shimizu, H., see Negishi, M. **33**, 15
Signore, A., V. Fiore, M. Chianelli, E. Procaccini, R. Barone, G. Ronga, M. Negri, Paolo Pozzilli, The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes **33**, 83
Sundkvist, G., see Littorin, B. **33**, 129
Suzuki, S., M. Ohtomo, Y. Satoh, H. Kawasaki, M. Hirai, A. Hirai, S. Hirai, M. Onoda, Y. Hinokio, H. Akai, T. Toyota, Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension **33**, 43

Takada, K., A. Kanatsuka, Y. Tokuyama, K. Yagui, M. Nishimura, Y. Saito, H. Makino, Islet amyloid polypeptide/amylin contents in pancreas change with increasing age in genetically obese and diabetic mice **33**, 153
Takemura, Y., see Inukai, T. **33**, 99
Tayama, K., see Inukai, T. **33**, 99
Testa, I., see Testa, R. **33**, 111
Testa, R., A.R. Bonfigli, L. Piantanelli, S. Manfrini, I. Testa, F. Gregorio, Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus **33**, 111
Tokuyama, Y., see Takada, K. **33**, 153
Toyota, T., see Suzuki, S. **33**, 43
Tsuji, M., see Inoue, S. **33**, 119

Uusimäki, A., see Qiao, Q. **33**, 191

Wada, H., see Ishizuka, T. **33**, 159
Wibell, L., see Littorin, B. **33**, 129

Wierusz-Wysocka, B., see Zozulińska, D.A. **33**, 139
Willis, J.A., R.S. Scott, L.J. Brown, L.V. Forbes, R.S. Schmidli, P.Z. Zimmet, I.R. MacKay, M.J. Rowley, Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus **33**, 89
Wurzinger, L.J., see Mellinghoff, A.C. **33**, 75
Wykretowicz, A., see Zozulińska, D.A. **33**, 139
Wysocki, H., see Zozulińska, D.A. **33**, 139

Yagui, K., see Takada, K. **33**, 153
Yamada, K., see Ishizuka, T. **33**, 159
Yamamoto, M., see Ishizuka, T. **33**, 159
Yamaoka, T., see Kunika, K. **33**, 181
Yasuda, K., see Ishizuka, T. **33**, 159
Yoshino, G., T. Hirano, T. Kazumi, Dyslipidemia in diabetes mellitus **33**, 1
Yue, D.K., see McGill, M.J. **33**, 173

Zimmet, P.Z., see Willis, J.A. **33**, 89
Zozulińska, D.A., B. Wierusz-Wysocka, H. Wysocki, A.E. Majchrzak, A. Wykretowicz, The influence of insulin-dependent diabetes mellitus (IDDM) duration on superoxide anion and hydrogen peroxide production by polymorphonuclear neutrophils **33**, 139

ELSEVIER

Diabetes Research and Clinical Practice 33 (1996) 203–206

DIABETES RESEARCH AND CLINICAL PRACTICE

Subject index

Volume 33 (1996)

Acarbose; Streptozotocin; Insulitis; Diabetes mellitus **33**, 15

Adipocytes; PKC mRNA; Insulin; Alternative splicing **33**, 159

Adult-onset diabetes mellitus; Anti-GAD; Islet cell antibodies; Insulin-treated diabetes mellitus **33**, 89

Albuminuria; Diabetic nephropathy; Glomerular charge barrier; Renal tubular reabsorption; Protein negative charge **33**, 181

Aldose reductase; Sorbitol dehydrogenase; Polyol pathway; Diabetes; Diabetic complications **33**, 31

Alternative splicing; PKC mRNA; Insulin; Adipocytes **33**, 159

Amylin; Islet amyloid polypeptide; Genetically diabetic mouse; Non-insulin-dependent (type 2) diabetes mellitus **33**, 153

Angiotensin-converting enzyme; Calcium channel blocker; Non-insulin-dependent diabetes mellitus; Hypertension; Insulin resistance **33**, 43

Anti-GAD; Adult-onset diabetes mellitus; Islet cell antibodies; Insulin-treated diabetes mellitus **33**, 89

Ascertainment; Epidemiology; Diabetes mellitus; Register; Prospective; Validation **33**, 129

Blood glucose; Metformin; Non-insulin dependent diabetes; Bread; Pasta **33**, 53

Bread; Metformin; Blood glucose; Non-insulin dependent diabetes; Pasta **33**, 53

Calcium channel blocker; Angiotensin-converting enzyme; Non-insulin-dependent diabetes mellitus; Hypertension; Insulin resistance **33**, 43

Captopril; Nifedipine; Prazosin; Hypertension; Diabetes; Insulin; C-peptide **33**, 59

Cardiovascular disease; Lipoprotein(a); Non-insulin-dependent diabetes mellitus; Glycaemic control; Diabetic complications **33**, 105

Cholesterol; Dyslipidemia; Triglyceride; VLDL; IDL; LDL; HDL; Lp(a); Postprandial lipemia **33**, 1

Colony-stimulating factor; Hydrogen peroxide production; Neutrophils; Diabetes mellitus; Phorbol myristate acetate **33**, 119

C-peptide; Nifedipine; Captopril; Prazosin; Hypertension; Diabetes; Insulin **33**, 59

Density; Viscosity; Plasma; Whole-blood; Type-1 diabetes **33**, 75

Diabetes; Aldose reductase; Sorbitol dehydrogenase; Polyol pathway; Diabetic complications **33**, 31

Diabetes; Dietary fat; Polyunsaturated fats; Fish oil; Proteinuria **33**, 21

Diabetes mellitus; Acarbose; Streptozotocin; Insulitis **33**, 15

Diabetes mellitus; Epidemiology; Register; Prospective; Ascertainment; Validation **33**, 129

Diabetes mellitus; Hydrogen peroxide production; Neutrophils; Phorbol myristate acetate; Colony-stimulating factor **33**, 119

Diabetes; Nifedipine; Captopril; Prazosin; Hypertension; Insulin; C-peptide **33**, 59

Diabetes; Rat; Diabetic nephropathy; Restricted feeding; Diet therapy **33**, 145

Diabetes; Risk predictor; Fasting hyperinsulinaemia; Overweight; Persistent impaired glucose tolerance **33**, 191

Diabetic complications; Aldose reductase; Sorbitol dehydrogenase; Polyol pathway; Diabetes **33**, 31

Diabetic complications; Cardiovascular disease; Lipoprotein(a); Non-insulin-dependent diabetes mellitus; Glycaemic control **33**, 105

Diabetic complications; Thrombomodulin; HbA_{1c}; Fructosamine **33**, 99

Diabetic nephropathy; Albuminuria; Glomerular charge barrier; Renal tubular reabsorption; Protein negative charge **33**, 181

Diabetic nephropathy; Rat; Diabetes; Restricted feeding; Diet therapy **33**, 145

Dietary fat; Diabetes; Polyunsaturated fats; Fish oil; Proteinuria **33**, 21

Diet therapy; Rat; Diabetes; Diabetic nephropathy; Restricted feeding **33**, 145

Dyslipidemia; Cholesterol; Triglyceride; VLDL; IDL; LDL; HDL; Lp(a); Postprandial lipemia **33**, 1

Epidemiology; Diabetes mellitus; Register; Prospective; Ascertainment; Validation **33**, 129

Ethnic; Non-insulin-dependent diabetes mellitus; Nephropathy; Hypertension; Proteinuria **33**, 173

Fasting hyperinsulinaemia; Risk predictor; Overweight; Diabetes; Persistent impaired glucose tolerance **33**, 191

Fetal haemoglobin; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Insulin treatment; Glycated haemoglobin **33**, 37

Fibrinolysis; Lipoprotein(a); Plasminogen activator inhibitor type 1; Non-insulin-dependent diabetes mellitus **33**, 111

Fish oil; Diabetes; Dietary fat; Polyunsaturated fats; Proteinuria **33**, 21

Fructosamine; Thrombomodulin; HbA_{1c}; Diabetic complications **33**, 99

Genetically diabetic mouse; Islet amyloid polypeptide; Amylin; Non-insulin-dependent (type 2) diabetes mellitus **33**, 153

Genetics; Glucagon receptor; Impaired glucose tolerance; Japanese; NIDDM; Restriction fragment length polymorphism **33**, 71

Glomerular charge barrier; Diabetic nephropathy; Albuminuria; Renal tubular reabsorption; Protein negative charge **33**, 181

Glucagon receptor; Genetics; Impaired glucose tolerance; Japanese; NIDDM; Restriction fragment length polymorphism **33**, 71

Glycaemic control; Cardiovascular disease; Lipoprotein(a); Non-insulin-dependent diabetes mellitus; Diabetic complications **33**, 105

Glycated haemoglobin; Fetal haemoglobin; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Insulin treatment **33**, 37

HbA_{1c}; Thrombomodulin; Fructosamine; Diabetic complications **33**, 99

HDL; Dyslipidemia; Cholesterol; Triglyceride; VLDL; IDL; LDL; Lp(a); Postprandial lipemia **33**, 1

Hepatic blood flow; NIDDM; Metformin; Insulin mediated liver metabolism **33**, 83

Hydrogen peroxide; Insulin-dependent diabetes mellitus; Polymorphonuclear neutrophils; Reactive oxygen species; Superoxide anion **33**, 139

Hydrogen peroxide production; Neutrophils; Diabetes mellitus; Phorbol myristate acetate; Colony-stimulating factor **33**, 119

Hypertension; Angiotensin-converting enzyme; Calcium channel blocker; Non-insulin-dependent diabetes mellitus; Insulin resistance **33**, 43

Hypertension; Nifedipine; Captopril; Prazosin; Diabetes; Insulin; C-peptide **33**, 59

Hypertension; Non-insulin-dependent diabetes mellitus; Nephropathy; Ethnic; Proteinuria **33**, 173

IDL; Dyslipidemia; Cholesterol; Triglyceride; VLDL; LDL; HDL; Lp(a); Postprandial lipemia **33**, 1

Impaired glucose tolerance; Genetics; Glucagon receptor; Japanese; NIDDM; Restriction fragment length polymorphism **33**, 71

Insulin-dependent diabetes mellitus; Fetal haemoglobin; Non-insulin-dependent diabetes mellitus; Insulin treatment; Glycated haemoglobin **33**, 37

Insulin-dependent diabetes mellitus; Polymorphonuclear neutrophils; Reactive oxygen species; Superoxide anion; Hydrogen peroxide **33**, 139

Insulin mediated liver metabolism; NIDDM; Metformin; Hepatic blood flow **33**, 83

Insulin; Nifedipine; Captopril; Prazosin; Hypertension; Diabetes; C-peptide **33**, 59

Insulin; PKC mRNA; Adipocytes; Alternative splicing **33**, 159

Insulin resistance; Angiotensin-converting enzyme; Calcium channel blocker; Non-insulin-dependent diabetes mellitus; Hypertension **33**, 43

Insulin-treated diabetes mellitus; Adult-onset diabetes mellitus; Anti-GAD; Islet cell antibodies **33**, 89

Insulin treatment; Fetal haemoglobin; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Glycated haemoglobin **33**, 37

Insulitis; Acarbose; Streptozotocin; Diabetes mellitus **33**, 15

Islet amyloid polypeptide; Amylin; Genetically diabetic mouse; Non-insulin-dependent (type 2) diabetes mellitus **33**, 153

Islet cell antibodies; Adult-onset diabetes mellitus; Anti-GAD; Insulin-treated diabetes mellitus **33**, 89

Japanese; Genetics; Glucagon receptor; Impaired glucose tolerance; NIDDM; Restriction fragment length polymorphism **33**, 71

LDL; Dyslipidemia; Cholesterol; Triglyceride; VLDL; IDL; HDL; Lp(a); Postprandial lipemia **33**, 1

Lipoprotein(a); Cardiovascular disease; Non-insulin-dependent diabetes mellitus; Glycaemic control; Diabetic complications **33**, 105

Lipoprotein(a); Fibrinolysis; Plasminogen activator inhibitor type 1; Non-insulin-dependent diabetes mellitus **33**, 111

Lp(a); Dyslipidemia; Cholesterol; Triglyceride; VLDL; IDL; LDL; HDL; Postprandial lipemia **33**, 1

Metformin; Blood glucose; Non-insulin dependent diabetes; Bread; Pasta **33**, 53

Metformin; NIDDM; Hepatic blood flow; Insulin mediated liver metabolism **33**, 83

Nephropathy; Non-insulin-dependent diabetes mellitus; Ethnic; Hypertension; Proteinuria **33**, 173

Neutrophils; Hydrogen peroxide production; Diabetes mellitus; Phorbol myristate acetate; Colony-stimulating factor **33**, 119

NIDDM; Genetics; Glucagon receptor; Impaired glucose tolerance; Japanese; Restriction fragment length polymorphism **33**, 71

NIDDM; Metformin; Hepatic blood flow; Insulin mediated liver metabolism **33**, 83

Nifedipine; Captopril; Prazosin; Hypertension; Diabetes; Insulin; C-peptide **33**, 59

Non-insulin-dependent diabetes mellitus; Angiotensin-converting enzyme; Calcium channel blocker; Hypertension; Insulin resistance **33**, 43

Non-insulin-dependent diabetes mellitus; Cardiovascular disease; Lipoprotein(a); Glycaemic control; Diabetic complications **33**, 105

Non-insulin-dependent diabetes mellitus; Fetal haemoglobin; Insulin-dependent diabetes mellitus; Insulin treatment; Glycated haemoglobin **33**, 37

Non-insulin-dependent diabetes mellitus; Lipoprotein(a); Fibrinolysis; Plasminogen activator inhibitor type 1 **33**, 111

Non-insulin-dependent diabetes mellitus; Nephropathy; Ethnic; Hypertension; Proteinuria **33**, 173

Non-insulin dependent diabetes; Metformin; Blood glucose; Bread; Pasta **33**, 53

Non-insulin-dependent (type 2) diabetes mellitus; Islet amyloid polypeptide; Amylin; Genetically diabetic mouse **33**, 153

Overweight; Risk predictor; Fasting hyperinsulinaemia; Diabetes; Persistent impaired glucose tolerance **33**, 191

Pasta; Metformin; Blood glucose; Non-insulin dependent diabetes; Bread **33**, 53

Persistent impaired glucose tolerance; Risk predictor; Fasting hyperinsulinaemia; Overweight; Diabetes **33**, 191

Phorbol myristate acetate; Hydrogen peroxide production; Neutrophils; Diabetes mellitus; Colony-stimulating factor **33**, 119

PKC mRNA; Insulin; Adipocytes; Alternative splicing **33**, 159

Plasma; Viscosity; Density; Whole-blood; Type-1 diabetes **33**, 75

Plasminogen activator inhibitor type 1; Lipoprotein(a); Fibrinolysis; Non-insulin-dependent diabetes mellitus **33**, 111

Polymorphonuclear neutrophils; Insulin-dependent diabetes mellitus; Reactive oxygen species; Superoxide anion; Hydrogen peroxide **33**, 139

Polyol pathway; Aldose reductase; Sorbitol dehydrogenase; Diabetes; Diabetic complications **33**, 31

Polyunsaturated fats; Diabetes; Dietary fat; Fish oil; Proteinuria **33**, 21

Postprandial lipemia; Dyslipidemia; Cholesterol; Triglyceride; VLDL; IDL; LDL; HDL; Lp(a) **33**, 1

Prazosin; Nifedipine; Captopril; Hypertension; Diabetes; Insulin; C-peptide **33**, 59

Prospective; Epidemiology; Diabetes mellitus; Register; Ascertainment; Validation **33**, 129

Protein negative charge; Diabetic nephropathy; Albuminuria; Glomerular charge barrier; Renal tubular reabsorption **33**, 181

Proteinuria; Diabetes; Dietary fat; Polyunsaturated fats; Fish oil **33**, 21

Proteinuria; Non-insulin-dependent diabetes mellitus; Nephropathy; Ethnic; Hypertension **33**, 173

Rat; Diabetes; Diabetic nephropathy; Restricted feeding; Diet therapy **33**, 145

Reactive oxygen species; Insulin-dependent diabetes mellitus; Polymorphonuclear neutrophils; Superoxide anion; Hydrogen peroxide **33**, 139

Register; Epidemiology; Diabetes mellitus; Prospective; Ascertainment; Validation **33**, 129

Renal tubular reabsorption; Diabetic nephropathy; Albuminuria; Glomerular charge barrier; Protein negative charge **33**, 181

Restricted feeding; Rat; Diabetes; Diabetic nephropathy; Diet therapy **33**, 145

Restriction fragment length polymorphism; Genetics; Glucagon receptor; Impaired glucose tolerance; Japanese; NIDDM **33**, 71

Risk predictor; Fasting hyperinsulinaemia; Overweight; Diabetes; Persistent impaired glucose tolerance **33**, 191

Sorbitol dehydrogenase; Aldose reductase; Polyol pathway; Diabetes; Diabetic complications **33**, 31

Streptozotocin; Acarbose; Insulitis; Diabetes mellitus **33**, 15

Superoxide anion; Insulin-dependent diabetes mellitus; Polymorphonuclear neutrophils; Reactive oxygen species; Hydrogen peroxide **33**, 139

Thrombomodulin; HbA_{1c}; Fructosamine; Diabetic complications **33**, 99

Triglyceride; Dyslipidemia; Cholesterol; VLDL; IDL; LDL; HDL; Lp(a); Postprandial lipemia **33**, 1

Type-1 diabetes; Viscosity; Density; Plasma; Whole-blood **33**, 75

Validation; Epidemiology; Diabetes mellitus; Register; Prospective; Ascertainment **33**, 129

Viscosity; Density; Plasma; Whole-blood; Type-1 diabetes **33**, 75

VLDL; Dyslipidemia; Cholesterol; Triglyceride; IDL; LDL; HDL; Lp(a); Postprandial lipemia **33**, 1

Whole-blood; Viscosity; Density; Plasma; Type-1 diabetes **33**, 75